Listen to this article Gaithersburg-based Novavax Inc. Tuesday announced its Nuvaxovid XBB.1.5 COVID-19 vaccine (NVX-CoV2601) ...

The emergency use listing is based on non-clinical data where the vaccine demonstrated immune responses against variants in ...

Novavax Inc. could now get its Covid-19 vaccine to nearly 200 more countries. It’s a critical win in the company’s bid to get its updated shot to as many markets as possible.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Erin Kissane, a co-founder of the COVID Tracking Project, rolled up her sleeve for the Novavax COVID-19 vaccine in ...

In an era where the world faces the monumental challenge of the COVID-19 pandemic, the role of vaccines cannot be ...

Novavax's updated COVID-19 vaccine is the only updated protein-based non-mRNA COVID-19 vaccine available in the European Union for individuals aged 12 and older Novavax is working closely with EU ...

The single-target vaccine is aimed at the XBB.1.5 Omicron subvariant of the coronavirus, which was dominant in the U.S. for ...

The U.S Food and Drug Administration approved the first chikungunya vaccine- Ixchiq Ixchiq is administered as a single dose intra-muscularly for individuals over 18 years of age and older who are ...

Novavax announced that Nuvaxovid XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the ...